NASDAQ
20.12.24
20:42 Uhr
2,200 US-Dollar
+0,010
+0,46 %
+0,46 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LEXARIA BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| Do | Lexaria Bioscience Corp.: Lexaria's Registered GLP-1 Study #4 Begins Dosing | 170 | ACCESSWIRE | Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss KELOWNA, BC / ACCESSWIRE / December 19, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the... ► Artikel lesen | |
| Mi | Lexaria Bioscience Corp. - 8-K, Current Report | - | SEC Filings | ||
| Mi | Lexaria gründet wissenschaftlichen Beirat zur Verbesserung der Arzneimittelverabreichungstechnologie | 3 | Investing.com Deutsch | ||
| Mi | Lexaria forms scientific advisory board to enhance drug delivery tech | 3 | Investing.com | ||
| Mi | Lexaria Bioscience Corp.: Lexaria Forms New Scientific Advisory Board | 175 | ACCESSWIRE | North American drug delivery development experts added to help guide Lexaria's strategic plans KELOWNA, BC / ACCESSWIRE / December 18, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the... ► Artikel lesen | |
| Di | Lexaria Bioscience Corp.: Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience | 189 | ACCESSWIRE | Dr. Gibson joining Lexaria's new scientific advisor board KELOWNA, BC / ACCESSWIRE / December 17, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator... ► Artikel lesen | |
| 09.12. | Lexaria Bioscience Corp.: Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 | 210 | ACCESSWIRE | Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide KELOWNA, BC / ACCESSWIRE / December 9, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW)... ► Artikel lesen | |
| 03.12. | Lexaria Bioscience CEO erwirbt Aktien im Wert von 118.391 US-Dollar | 1 | Investing.com Deutsch | ||
| 26.11. | Lexaria Bioscience Corp. - 10-K, Annual Report | - | SEC Filings | ||
| 26.11. | Lexaria Bioscience Corp.: Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs | 231 | ACCESSWIRE | Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and moreGLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come KELOWNA... ► Artikel lesen | |
| 25.11. | Lexaria Bioscience Corp.: Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled | 161 | ACCESSWIRE | DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / November 25, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company"... ► Artikel lesen | |
| 20.11. | Lexaria Bioscience Corp.: ALL Study Groups using DehydraTECH Processing Outperform Rybelsus in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study | 219 | ACCESSWIRE | DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in both body weight-loss, by 11.53% and 10.65%... ► Artikel lesen | |
| 14.11. | Lexaria startet einzigartige Studie zur Arzneimittelverteilung | 2 | Investing.com Deutsch | ||
| 14.11. | Lexaria Bioscience Corp.: Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study | 154 | ACCESSWIRE | World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / November 14, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the... ► Artikel lesen | |
| 13.11. | Lexaria Bioscience Corp.: Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss | 247 | ACCESSWIRE | DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global... ► Artikel lesen | |
| 07.11. | Lexaria Bioscience Corp.: Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments | 258 | ACCESSWIRE | DehydraTECH for GLP-1 being optimized for global pharmaceutical use KELOWNA, BC / ACCESSWIRE / November 7, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a... ► Artikel lesen | |
| 24.10. | Lexaria meldet vielversprechende Ergebnisse zur Blutzuckerkontrolle in Tierstudie | 4 | Investing.com Deutsch | ||
| 24.10. | Lexaria reports promising blood sugar control in animal study | 2 | Investing.com | ||
| 24.10. | Lexaria Bioscience Corp.: Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study | 223 | ACCESSWIRE | DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ACCESSWIRE / October 24, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)... ► Artikel lesen | |
| 22.10. | Lexaria vermeldet Fortschritte bei Studie zu Abnehmmittel | 2 | Investing.com Deutsch |
Seite:
1 2 3 4 5 Weiter >>
84 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EMEIS | 5,162 | +1,04 % | emeis announces €251m in disposals of real estate and operating assets since the beginning of October | Nearly €900 million in disposals completed since mid-2022 or secured to date Disposal of activities in Chile and the Czech Republic
Regulatory News:
emeis (Paris:EMEIS) today announced... ► Artikel lesen | |
| EMPOWER CLINICS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.07.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 30.07.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.07.2024ISIN NameCA29246V2030 EMPOWER... ► Artikel lesen | |
| NANO-X IMAGING | 6,770 | +3,04 % | Nano-X Imaging LTD.: Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication | Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication... ► Artikel lesen | |
| GLOBAL HEMP GROUP | 0,005 | -41,18 % | Global Hemp Group Inc (2): Global Hemp investor sells 1.35 million warrants | ||
| BUTTERFLY NETWORK | 3,075 | +3,71 % | Butterfly Network (NYSE:BFLY) Shares Down 6.3% - What's Next? | ||
| CARMAT | 0,960 | -0,52 % | Successful first "Aeson European User Meeting", marking an important step in the deployment of CARMAT's artificial heart | More than 100 healthcare professionals from 41 hospitals and 10 countries rallied to share their experiences of the Aeson® artificial heart All hospitals taking part in the event confirmed... ► Artikel lesen | |
| GOODRX | 4,450 | -0,89 % | GoodRx stock rises 5% after new CEO appointment | ||
| JOINT CORP | 10,300 | +0,10 % | The Joint Corp. Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | SCOTTSDALE, Ariz., Oct. 15, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT) ("The Joint or "the Company"), the nation's largest franchisor of chiropractic care through The Joint Chiropractic®... ► Artikel lesen | |
| TALKSPACE | 2,985 | -0,83 % | Espresa Partners with Talkspace to Boost Employee Well-Being with Accessible Mental Health Benefits | Espresa has partnered with Talkspace to expand mental health support for employees. Through Espresa's platform, clients now have access to Talkspace's 5,000+ licensed therapists, offering secure, on-demand... ► Artikel lesen | |
| MIMEDX | 9,110 | +0,33 % | MiMedx Group, Inc: MIMEDX Files Patent Infringement Lawsuit Against Surgenex | ||
| PROCEPT BIOROBOTICS | 81,25 | +0,58 % | PROCEPT BioRobotics Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance | SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| HYPERFINE | 0,885 | -4,73 % | Hyperfine, Inc.: Hyperfine Expands Global Market Reach with New Distribution Partnerships in European and Middle Eastern Markets | Strategic agreements set the stage for further global adoption of portable MR brain imaging technology, fueling expansion plans for 2025.
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health... ► Artikel lesen | |
| ATRICURE | 30,725 | +2,25 % | Pre-market Movers: ASP Isotopes, NerdWallet, Reddit, AtriCure, Qorvo | OLATHE (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.05 A.M. ET).In the Green ASP Isotopes Inc. (ASPI) is up over 44% at $8.33.
NerdWallet... ► Artikel lesen | |
| BIOMERICA | 0,275 | +3,46 % | BIOMERICA INC - S-8, Securities to be offered to employees in employee benefit plans | ||
| PROGYNY | 14,350 | +1,13 % | Progyny, Inc. Announces Third Quarter 2024 Results | Sales Season Yields Over 80 New Clients, 1.1 Million New Covered LivesSelected by a Leading National Health Plan and a Regional Health Plan as Their Preferred Partner1.5 Million Lives Adopt Newest... ► Artikel lesen |
LEXARIA BIOSCIENCE CORP gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +0,46 % bei einem Aktienkurs von 2,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXARIA BIOSCIENCE CORP finden Sie auf Wallstreet Online.
